secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001140361-24-012128
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma reports FY 2023 net loss of $10M; advances APX3330 Phase 3 and RYZUMVI launch
--------------------------------------------------------------------------------

- Cash $50.5M at Dec 31, 2023; management expects to fund operations into mid-2025.
- FY 2023 revenue $19.0M (incl. $10M Viatris milestone) vs $39.9M in 2022; net loss $10.0M ($0.46/share) vs net income $17.9M in 2022.
- APX3330 SPA submitted for Phase 3 registrational trial in diabetic retinopathy; FDA agreed on primary endpoint.
- RYZUMVI (phentolamine) approved Sep 2023; launch expected H1 2024; Viatris to fund further development for presbyopia and post-refractive surgery.
- Leadership changes: George Magrath CEO (Nov 2023), new CFO and CSDO appointed Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/0001140361-24-012128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/ef20023531_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-012128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer